retatrutide what to expect is being called the strongest weight-loss drug ever studied… and it's not even approved yet. 👀 Early Phase 3 results: the top dose averaged ~28% body weight loss — about 70 Retatrutide Dosing Guide for Researchers

SIRT1 has neuroprotective effects

Retatrutide is investigational and is not currently FDA-approved

Importantly, users tend to follow one of two primary behavioral pathways either eating fewer meals/snacks or consuming smaller portions rather than combining both, the report said

Phoenix, AZ Frequently asked questions In the STEP 1 trial published in The New England Journal of Medicine (Wilding et al., 2021), participants on weekly 2.4 mg semaglutide lost an average of 14.9% of body weight at 68 weeks versus 2.4% on placebo

If these findings translate into significant reductions in hard clinical endpointsparticularly cardiovascular events, kidney outcomes, and mortalityretatrutide has the potential to become a truly transformative therapy, not just another weight-loss drug